NASDAQ:CBMG - Cellular Biomedicine Group Stock Price, News, & Analysis

Cellular Biomedicine Group trades on the NASDAQ under the ticker symbol "CBMG."

Cellular Biomedicine Group declared that its Board of Directors has initiated a share repurchase program on Sunday, June 4th 2017, which permits the company to repurchase $10,000,000.00 in shares, according to EventVestor. This repurchase authorization permits the company to reacquire shares of its stock through open market purchases. Stock repurchase programs are usually a sign that the company's leadership believes its shares are undervalued.

Cellular Biomedicine Group Inc (NASDAQ:CBMG) released its quarterly earnings results on Tuesday, February, 19th. The biotechnology company reported ($0.45) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of ($0.44) by $0.01. The biotechnology company earned $0.03 million during the quarter, compared to the consensus estimate of $0.05 million. Cellular Biomedicine Group had a negative return on equity of 42.82% and a negative net margin of 17,386.16%. View Cellular Biomedicine Group's Earnings History.

Cellular Biomedicine Group is scheduled to release their next quarterly earnings announcement on Monday, May 6th 2019. View Earnings Estimates for Cellular Biomedicine Group.

3 equities research analysts have issued twelve-month price targets for Cellular Biomedicine Group's shares. Their forecasts range from $26.00 to $38.00. On average, they anticipate Cellular Biomedicine Group's share price to reach $32.00 in the next year. This suggests a possible upside of 91.7% from the stock's current price. View Analyst Price Targets for Cellular Biomedicine Group.

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cellular Biomedicine Group in the last year. There are currently 1 hold rating and 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Cellular Biomedicine Group.

Media headlines about CBMG stock have trended somewhat negative recently, InfoTrie Sentiment Analysis reports. The research group identifies positive and negative news coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Cellular Biomedicine Group earned a coverage optimism score of -1.1 on InfoTrie's scale. They also gave news articles about the biotechnology company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an effect on the company's share price in the near future.

Some companies that are related to Cellular Biomedicine Group include Iovance Biotherapeutics (IOVA), Editas Medicine (EDIT), Fate Therapeutics (FATE), Coherus Biosciences (CHRS), Autolus Therapeutics (AUTL), Sangamo Therapeutics (SGMO), BioCryst Pharmaceuticals (BCRX), Vericel (VCEL), NanoString Technologies (NSTG), Nightstar Therapeutics (NITE), Cellectis (CLLS), BAVARIAN NORDIC/S (BVNRY), Osiris Therapeutics (OSIR), Heska (HSKA) and Acorda Therapeutics (ACOR).

Based on aggregate information from My MarketBeat watchlists, some companies that other Cellular Biomedicine Group investors own include Exelixis (EXEL), Crispr Therapeutics (CRSP), ACADIA Pharmaceuticals (ACAD), Viewray (VRAY), Micron Technology (MU), Adaptimmune Therapeutics (ADAP), Fate Therapeutics (FATE), Nektar Therapeutics (NKTR), Novavax (NVAX) and Anthera Pharmaceuticals (ANTH).

Cellular Biomedicine Group's stock is owned by a number of of retail and institutional investors. Top institutional investors include BlackRock Inc. (3.58%), Northern Trust Corp (0.88%), Geode Capital Management LLC (0.69%), Geode Capital Management LLC (0.70%), Bank of New York Mellon Corp (0.21%) and Rhumbline Advisers (0.08%). Company insiders that own Cellular Biomedicine Group stock include Andrew K Chan, Tony Liu, Wen Tao Liu and Yihong Yao. View Institutional Ownership Trends for Cellular Biomedicine Group.

CBMG stock was sold by a variety of institutional investors in the last quarter, including Northern Trust Corp. View Insider Buying and Selling for Cellular Biomedicine Group.

CBMG stock was acquired by a variety of institutional investors in the last quarter, including BlackRock Inc., Geode Capital Management LLC, Geode Capital Management LLC, Bank of America Corp DE, MetLife Investment Advisors LLC, Bank of New York Mellon Corp, Rhumbline Advisers and Metropolitan Life Insurance Co. NY. Company insiders that have bought Cellular Biomedicine Group stock in the last two years include Andrew K Chan, Tony Liu and Yihong Yao. View Insider Buying and Selling for Cellular Biomedicine Group.

Shares of CBMG can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of CBMG stock can currently be purchased for approximately $16.69.

Cellular Biomedicine Group has a market capitalization of $301.92 million and generates $220,000.00 in revenue each year. The biotechnology company earns $-38,930,000.00 in net income (profit) each year or ($2.04) on an earnings per share basis.

The official website for Cellular Biomedicine Group is http://www.cellbiomedgroup.com.

Cellular Biomedicine Group's mailing address is 19925 STEVENS CREEK BLVD. SUITE 100, CUPERTINO CA, 95014. The biotechnology company can be reached via phone at 408-973-7884 or via email at [email protected]